Gilles Seydoux, PharmD

Co-Founder, Board Director & Corporate Secretary

Dr. Seydoux is a Board Director and the Corporate Secretary of the Company. He is a member of the Cytovia Executive Committee. Prior to this he was the Company responsible for Corporate and Product Strategy, Commercial Planning, Business Development, Communication, and Corporate Affairs.

​

He is also a Co-Founder, Investor, and Board Director of Cytovia and member of the Investment Committee.

He has over 40 years of experience in the Pharmaceutical Industry, including 22 years in the US. He was until November 2018, at GSK, Global Commercial Lead on several assets in Rare Diseases and Diabetes, both launched or in clinical development. At GSK, he managed the $3 billion Acquisition of Reliant Pharmaceuticals. Prior to joining GSK, he held several positions at Wyeth (now Pfizer) including VP, Commercial Planning for International/Europe and VP, Head of the Enbrel immuno-inflammation global franchise where he led the global launch execution of Enbrel, one of the top 5 global pharmaceutical biological products in sales. Previous experiences include Marketing, Commercial and Sales Management roles at Wyeth in France, as Business Unit Head of the Primary Care and Neuroscience Franchise, P&G Pharmaceuticals (France Associate Country Manager and previously Marketing Director in both France and the US) and Merck (Marketing Director Cardiovascular Franchise).

Gilles Seydoux holds a Pharm. D degree from Paris V University and is a citizen of both the United States and France.

Gilles Seydoux is also Chairman of the Board of Holding Carsey SA, a French company.